Next Article in Journal
Three-Step Thermal Drawing for Rapid Prototyping of Highly Customizable Microneedles for Vascular Tissue Insertion
Next Article in Special Issue
What Drives Innovation: The Canadian Touch on Liposomal Therapeutics
Previous Article in Journal
A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs
Previous Article in Special Issue
Biodistribution of a Radiolabeled Antibody in Mice as an Approach to Evaluating Antibody Pharmacokinetics
Open AccessPerspective

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

1
College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK S7N 2Z4, Canada
2
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
*
Author to whom correspondence should be addressed.
Pharmaceutics 2019, 11(3), 99; https://doi.org/10.3390/pharmaceutics11030099
Received: 30 January 2019 / Revised: 18 February 2019 / Accepted: 19 February 2019 / Published: 26 February 2019
(This article belongs to the Special Issue Drug Delivery Technology Development in Canada)
Parenteral amphotericin B has been considered as first-line therapy in the treatment of systemic fungal and parasitic infections, however its use has been associated with a number of limitations including affordability, accessibility, and an array of systemic toxicities. Until very recently, it has been very challenging to develop a bioavailable formulation of amphotericin B due to its physical chemical properties, limited water and lipid solubility, and poor absorption. This perspective reviews several novel oral Amphotericin B formulations under development that are attempting to overcome these limitations. View Full-Text
Keywords: oral formulation; amphotericin B; fungal infections; parasitic infections; developing world; drug delivery oral formulation; amphotericin B; fungal infections; parasitic infections; developing world; drug delivery
Show Figures

Figure 1

MDPI and ACS Style

Cuddihy, G.; Wasan, E.K.; Di, Y.; Wasan, K.M. The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized? Pharmaceutics 2019, 11, 99.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop